Workman Alan D, Bleier Benjamin S
Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
World J Otorhinolaryngol Head Neck Surg. 2020 Jun 23;6(4):230-234. doi: 10.1016/j.wjorl.2020.06.002. eCollection 2020 Dec.
Aspirin-exacerbated respiratory disease (AERD) patients with CRSwNP suffer from reduced quality of life, reduced economic productivity, and higher risk of depression and sleep dysfunction. These patients often require frequent medical and surgical therapy, including functional endoscopic sinus surgery for recalcitrant disease. Given this severity, anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP, including Omalizumab and Dupilumab. Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologics are comparable to the current standard of care in the short term, but there is a lack of long-term data and standardized regimen that makes direct comparison difficult. Biologic therapies additionally require continuous use to avoid recurrence, and currently cost many times more than existing medical or surgical therapies.
阿司匹林加重性呼吸道疾病（AERD）合并慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）的患者生活质量下降、经济生产力降低，患抑郁症和睡眠功能障碍的风险更高。这些患者通常需要频繁的药物和手术治疗，包括针对顽固性疾病的功能性鼻内镜鼻窦手术。鉴于病情的严重性，正在研究抗2型生物制剂用于这一CRSwNP患者亚组，包括奥马珠单抗和度普利尤单抗。初步数据表明，生物制剂治疗后与鼻窦鼻相关生活质量问卷-22（SNOT-22）相关的生活质量改善在短期内与当前的标准治疗相当，但缺乏长期数据和标准化方案，难以进行直接比较。此外，生物治疗需要持续使用以避免复发，目前其费用比现有的药物或手术治疗高出许多倍。
